MDR1-EXPRESSING CD4(+) T CELLS WITH TH1.17 FEATURES RESIST TO NEOADJUVANT CHEMOTHERAPY AND ARE ASSOCIATED WITH BREAST CANCER CLINICAL RESPONSE

BACKGROUND: Multidrug resistance-1 (MDR1) transporter limits the intracellular accumulation of chemotherapies (paclitaxel, anthracyclines) used in breast cancer (BC) treatment. In addition to tumor cells, MDR1 is expressed on immune cell subsets in which it confers chemoresistance. Among human T cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Roio, Anthony, Hubert, Margaux, Besson, Laurie, Bossennec, Marion, Rodriguez, Céline, Grinberg-Bleyer, Yenkel, Lalle, Guilhem, Moudombi, Lyvia, Schneider, Raphael, Degletagne, Cyril, Treilleux, Isabelle, Campbell, Daniel J, Metzger, Séverine, Duhen, Thomas, Trédan, Olivier, Caux, Christophe, Ménétrier-Caux, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632904/
https://www.ncbi.nlm.nih.gov/pubmed/37940345
http://dx.doi.org/10.1136/jitc-2023-007733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632904/
https://www.ncbi.nlm.nih.gov/pubmed/37940345
http://dx.doi.org/10.1136/jitc-2023-007733

Ejemplares similares